New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 22, 2013
12:50 EDTMDGNLegal & General Investment reports 6.04% stake in Medgenics
News For MDGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 15, 2014
08:10 EDTMDGNMedgenics reports Q3 EPS (21c) vs. (33c) last year
Gross research and development expenses for the three months ended September 30 decreased to $2.28M from $2.45M for same period in 2013. This decrease was due mainly to a decrease in subcontractor costs. Net R&D expenses for the three months ended September 30 decreased to $1.57M from $2.34M for the same period in 2013. The decrease in net R&D expenses was due to an increase of $0.61M in the participation by the Israeli Office of the Chief Scientist in addition to the decrease in gross R&D expenses. General and administrative expenses for the three months ended September 30 were $2.31M, decreasing from $2.56M for the same period in 2013 primarily due to a decrease in professional fees.
08:08 EDTMDGNMedgenics reports positive initial clinical data of MDGN-201
Subscribe for More Information
October 14, 2014
06:58 EDTMDGNMedgenics to host conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use